Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I

DemeRx

1 Drug Candidate

DemeRx is a clinical-stage biotech developing noribogaine (DMX-1001), a non-psychedelic active metabolite of ibogaine, as a treatment for alcohol use disorder. DMX-1001 promotes neuroplasticity to repair neural circuits damaged by chronic alcohol use. Phase 1b completed with favorable safety; Phase 2 AUD trial planned for 2026, supported by a $1.7M NIH SBIR grant.

Drug Pipeline

1

DMX-1001

Ibogaine
Phase I
Alcohol Use Disorder (AUD)

Noribogaine (ibogaine metabolite), oral formulation. Phase 1b completed in healthy volunteers with favourable safety profile. NIH SBIR-funded Phase 2 AUD trial planned 2026.

Quick Facts

Type
Private Biotech
Lead Stage
Phase I
Website
Visit